Enzyme replacement therapy for murine mucopolysaccharidosis type VII

Mark S. Sands, Carole Vogler, John W. Kyle, Jeffrey H. Grubb, Beth Levy, Nancy Galvin, William S. Sly, Edward H. Birkenmeier

Research output: Contribution to journalArticlepeer-review

180 Scopus citations

Abstract

Recombinant mouse β-glucuronidase administered intravenously to newborn mice with mucopolysaccharidosis type VII (MPS VII) is rapidly cleared from the circulation and localized in many tissues. Here we determine the tissue distribution of injected enzyme and describe its effects on the histopathology in 6-wk-old MPS VII mice that received either one injection of 28,000 U recombinant β-glucuronidase at 5 wk of age or received six injections of 28,000 U given at weekly intervals beginning at birth. These mice were compared with untreated 6-wk-old MPS VII mice. The single injection decreased lysosomal distention in the fixed tissue macrophage system. MPS VII mice that received multiple injections had 27.8, 3.5, and 3.3% of normal levels of β-glucuronidase in liver, spleen, and kidney, respectively. Brain had detectable β-glucuronidase, ranging from 2.0-12.1% of normal. Secondary elevations of α-galactosidase and β-hexosaminidase in brain, spleen, liver, and kidney were decreased compared with untreated MPS VII mice. Although no improvement was observed in chondrocytes, glia, and some neurons, the skeleton had less clinical and pathological evidence of disease and the brain had reduced lysosomal storage in meninges and selected neuronal groups. These data show that recombinant β-glucuronidase treatment begun in newborn MPS VII mice provides enzyme to most tissues and significantly reduces or prevents the accumulation of lysosomal storage during the first 6 wk of life. Whether therapy begun later in life can achieve this level of correction remains to be established.

Original languageEnglish
Pages (from-to)2324-2331
Number of pages8
JournalJournal of Clinical Investigation
Volume93
Issue number6
DOIs
StatePublished - Jun 1994

Keywords

  • Sly syndrome
  • animal models
  • central nervous system
  • lysosomal storage diseases
  • β-glucuronidase

Fingerprint

Dive into the research topics of 'Enzyme replacement therapy for murine mucopolysaccharidosis type VII'. Together they form a unique fingerprint.

Cite this